

**Statement of Financial Results for the quarter ended 30th June 2022**

Particulars	Quarter ended			Year ended
	30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
1 Revenue from Operations	12,893	10,380	10,813	44,016
2 Other Income	122	126	41	299
3 <b>Total Income</b>	<b>13,015</b>	<b>10,506</b>	<b>10,854</b>	<b>44,315</b>
4 <b>Expenses</b>				
(a) Cost of Materials Consumed	2,126	2,301	2,087	8,813
(b) Purchases of Stock-in-Trade	2,012	1,659	1,484	7,890
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	216	(339)	(76)	(2,521)
(d) Employee Benefits Expense	2,708	2,504	2,360	9,997
(e) Finance Costs	11	6	13	52
(f) Depreciation and Amortisation Expense	383	378	396	1,566
(g) Other Expenses	3,047	2,904	2,663	11,201
<b>Total Expenses</b>	<b>10,503</b>	<b>9,413</b>	<b>8,927</b>	<b>36,998</b>
5 <b>Profit before tax (3-4)</b>	<b>2,512</b>	<b>1,093</b>	<b>1,927</b>	<b>7,317</b>
6 Income tax expenses				
a. Current Tax	658	410	578	2,276
b. Deferred Tax	33	(69)	(9)	(107)
7 <b>Profit for the period (5-6)</b>	<b>1,821</b>	<b>752</b>	<b>1,358</b>	<b>5,148</b>
8 <b>Other Comprehensive Income</b>				
(i) Items that will not be reclassified to Profit or Loss	(9)	(24)	(4)	(36)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	2	8	1	11
<b>Other Comprehensive Income Net of Tax</b>	<b>(7)</b>	<b>(16)</b>	<b>(3)</b>	<b>(25)</b>
9 <b>Total Comprehensive Income for the period (7+8)</b>	<b>1,814</b>	<b>736</b>	<b>1,355</b>	<b>5,123</b>
10 Paid-up Equity Share Capital (Face Value of the share - Rs. 8/- each)	1,323	1,323	1,323	1,323
11 Other Equity				24,254
12 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):				
(a) Basic	11.01	4.55	8.21	31.13
(b) Diluted	11.01	4.55	8.21	31.13

**Notes:**

- The above Unaudited Financial Results have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meetings held on August 02, 2022.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- The figures of the quarter ended 31 March, 2022 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures upto 31 December, 2021, which were subjected to limited review.
- The Company exercised the option of lower tax rate under section 115 BAA of Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 effective April 01, 2022. Accordingly, the Company has adopted the new tax rate of 25.17% which has resulted in a reversal of deferred tax balances of Rs 46 lakhs on account of remeasurement of deferred tax balances as at 31st March, 2022 and is recognised in the financial results for the period ended 30th June, 2022
- Previous period's figures have been regrouped/reclassified wherever necessary.

For RPG Life Sciences Limited

Yugal Sikri  
Managing Director  
Mumbai, August 02, 2022